The total output value of China's pharmaceutical packaging industry has accounted for more than 10% of the total output value of the national packaging industry, which is much higher than the proportion of the entire pharmaceutical industry in the total industrial output value of the country. With the implementation of the new version of GMP, the industry has put forward new requirements for the hardware equipment of pharmaceutical companies, which has achieved the growth of a number of pharmaceutical equipment companies, and has also achieved an opportunity for the upgrading of the pharmaceutical packaging materials industry. In recent years, the pharmaceutical industry has fully realized the importance of good packaging design, as it faces continuous pressure to help patients comply with medication regulations, meet regulatory requirements, and increase the longevity and attractiveness of brands. At the same time, pharmaceutical companies must innovate and become more efficient to counter the growing threat of counterfeit medicines. Therefore, the demand of pharmaceutical companies for pharmaceutical packaging market will be increasing. At the same time, with the continuous improvement of Chinese residents' living standards and health concepts, coupled with the continuous increase of government investment in medical and health services, in the future, my country's pharmaceutical packaging market will usher in rapid growth. Analysts pointed out that the future of China's pharmaceutical packaging industry mergers and acquisitions will enter a high incidence stage. In January 2013, the Ministry of Industry and Information Technology, the Ministry of Finance, the National Development and Reform Commission and other departments jointly issued the "Guiding Opinions on Accelerating the Merger and Reorganization of Enterprises in Key Industries". The "Opinions" clarified the goals and tasks of the merger and reorganization of enterprises in the pharmaceutical industry. By 2015, the sales revenue of the top 100 enterprises will account for more than 50% of the whole industry, and the market share of the top 20 enterprises in the sales of major varieties of essential drugs will reach 80%, realizing the large-scale and intensive production of essential drugs. Encourage the integration of upstream and downstream between R & D and production, raw materials and preparations, traditional Chinese medicine and Chinese patent medicine enterprises, improve the industrial chain, and improve the efficiency of resource allocation. At present, most of China's pharmaceutical packaging enterprises are small and medium-sized enterprises. With the acceleration of merger and reorganization of the pharmaceutical industry, higher requirements will be put forward for the production capacity and product quality of upstream pharmaceutical packaging enterprises. The change of external market demand will promote the development of China's pharmaceutical packaging towards scale, and merger and reorganization is undoubtedly one of the faster ways to achieve scale.